Inpatient prescribing trends and differences in drug acquisition costs of long-acting injectable subcutaneous risperidone versus paliperidone palmitate: A single-center medication use evaluation
Inpatient institutions may have an opportunity to decrease drug costs by switching from PP1M to SC-RLAI1M as a formulary-preferred medication when appropriate. However, administrators should consider institution-specific costs as well as product availability for patients after discharge.
Authors
- Andrew Chantha Hean (ORCID: https://orcid.org/0000-0002-8340-2296)
- Casey M. Tiefenthaler (ORCID: https://orcid.org/0000-0002-2417-0528)
- Jung Hoon Park (ORCID: https://orcid.org/0009-0002-3030-3806)
- Craig Stevens
- Cadence Wong
Institutions
- University of San Diego (US)
- UC San Diego Health System (US)
- University of Montana (US)
- Western University of Health Sciences (US)
Publication Details
- Journal
- Mental Health Clinician
- Published
- 2026-02-01
- DOI
- https://doi.org/10.9740/mhc.2026.02.007
- Primary Topic
- Pharmacovigilance and Adverse Drug Reactions
- Type
- article
- Field-Weighted Citation Impact
- 0.00